#1 Clinical Trials Search in Europe

Gozetotide Alf-18

Gozetotide Alf-18, also known as [18F]PSMA-11, is an innovative radiopharmaceutical being studied in clinical trials for its potential in cancer imaging. This article explores the use of this drug in ongoing research for various types of cancer, including thyroid, head and neck, and liver cancers. We’ll delve into the objectives, methods, and potential impacts of these trials on cancer diagnosis and treatment.

Table of Contents

What is GOZETOTIDE ALF-18?

GOZETOTIDE ALF-18, also known as [18F]PSMA-11 or [18F]PSMA-HBED, is a radiopharmaceutical being studied for its potential in cancer imaging[1][2]. It’s a special type of drug that contains a small amount of radioactive material, which helps doctors see certain types of cancer cells more clearly on imaging scans.

How It Works

GOZETOTIDE ALF-18 works by targeting a specific protein called Prostate-Specific Membrane Antigen (PSMA). While PSMA is commonly associated with prostate cancer, researchers have found that it’s also present in other types of cancer cells[1][2]. When injected into the body, GOZETOTIDE ALF-18 attaches to these PSMA proteins, allowing doctors to see cancer cells more clearly on a special type of scan called a PET (Positron Emission Tomography) scan.

Medical Conditions Being Studied

Current clinical trials are investigating the use of GOZETOTIDE ALF-18 in several types of cancer:

  • Head and neck squamous cell carcinoma (HNSCC): A type of cancer that starts in the cells lining the mouth, nose, or throat[1]
  • Thyroid carcinoma: Cancer that develops in the thyroid gland[1]
  • Hepatocellular carcinoma (HCC): The most common type of primary liver cancer[2]

Current Clinical Trials

Two main clinical trials are currently studying GOZETOTIDE ALF-18:

  1. A study focusing on advanced thyroid and head and neck cancer[1]
  2. A study on liver cancer (hepatocellular carcinoma)[2]

These trials aim to evaluate how well GOZETOTIDE ALF-18 can detect cancer cells compared to other imaging methods currently in use.

How GOZETOTIDE ALF-18 is Administered

GOZETOTIDE ALF-18 is given as a solution for injection through an intravenous injection (directly into a vein)[1][2]. The dose is calculated based on the patient’s weight, with a maximum dose ranging from 2.2 to 4.4 MBq/kg (megabecquerels per kilogram of body weight).

Potential Benefits

The potential benefits of using GOZETOTIDE ALF-18 include:

  • More accurate detection of cancer cells[1][2]
  • Improved staging of cancer, which helps determine how far the cancer has spread[2]
  • Better planning for treatment[2]
  • Potential to predict patient outcomes[2]

Who Can Participate in the Studies?

While specific criteria may vary between studies, general eligibility includes:

  • Being 18 years of age or older[1][2]
  • Having a confirmed diagnosis of the specific cancer being studied[1][2]
  • Being willing and able to provide informed consent[1][2]

Some conditions that may prevent participation include:

  • Having other active cancers besides the one being studied[1][2]
  • Being pregnant or breastfeeding[1][2]
  • Having a history of prostate cancer (for the liver cancer study)[2]

Safety Considerations

As with any medical procedure involving radiation, there are some safety considerations:

  • The amount of radiation used is carefully controlled to minimize risks[1][2]
  • Pregnant women are excluded from the studies due to potential risks to the fetus[1][2]
  • The studies are closely monitored by medical professionals to ensure patient safety[1][2]

It’s important to note that GOZETOTIDE ALF-18 is still being studied, and more research is needed to fully understand its benefits and potential risks. If you’re interested in participating in these studies or learning more about this radiopharmaceutical, speak with your healthcare provider.

Aspect Details
Drug Name Gozetotide Alf-18 ([18F]PSMA-11)
Trial Types Phase II clinical trials
Cancer Types Studied Thyroid cancer, Head and neck squamous cell carcinoma, Hepatocellular carcinoma
Main Objectives Evaluate uptake in lesions, Compare with other imaging techniques, Assess diagnostic accuracy
Imaging Comparisons [18F]FDG PET, Radioiodine thyroid scintigraphy, [18F]Choline PET
Key Endpoints Lesion detection rate, Overall survival, Progression-free survival, Tumor-to-background ratio
Participant Criteria 18+ years old, Confirmed cancer diagnosis, Measurable lesions or high metastasis risk
Administration Intravenous injection
Dosage 2.2-4.4 MBq/kg (varies by trial)

FAQ

  • What is Gozetotide Alf-18 and how is it used in clinical trials? Gozetotide Alf-18, also known as [18F]PSMA-11, is a radiopharmaceutical used in PET imaging. In clinical trials, it's being studied for its ability to detect and image various types of cancer, including thyroid, head and neck, and liver cancers.
  • What types of cancer are being studied with Gozetotide Alf-18? Current clinical trials are focusing on thyroid cancer, head and neck squamous cell carcinoma, and hepatocellular carcinoma (liver cancer).
  • How does Gozetotide Alf-18 compare to other imaging techniques? The trials aim to compare Gozetotide Alf-18 PET imaging with other established techniques like [18F]FDG PET, radioiodine thyroid scintigraphy, and [18F]Choline PET. These comparisons will help determine the effectiveness and potential advantages of Gozetotide Alf-18 in cancer imaging.
  • What are the main objectives of these clinical trials? The main objectives include demonstrating the uptake of Gozetotide Alf-18 in cancer lesions, comparing its effectiveness to other imaging techniques, assessing its diagnostic accuracy, and evaluating its impact on patient survival and disease progression.
  • Who can participate in these clinical trials? Generally, participants must be 18 years or older, have a confirmed diagnosis of the specific cancer being studied, and meet other criteria such as having measurable lesions or being at high risk for metastases. Exclusion criteria may include pregnancy, active malignancies other than the studied cancer, or a history of prostate cancer in some cases.

Ongoing Clinical Trials on Gozetotide Alf-18

  • Study on [18F]PSMA-11 PET Imaging for Patients with Advanced Thyroid and Head and Neck Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on F-18 PSMA-11 PET Imaging for Liver Cancer in Patients to Evaluate Survival

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Gozetotide Alf-18: A radiopharmaceutical also known as [18F]PSMA-11, used in PET imaging for cancer detection and staging.
  • PET: Positron Emission Tomography, an imaging technique that uses radioactive tracers to visualize and measure metabolic processes in the body.
  • Radiopharmaceutical: A drug containing a radioactive substance used for diagnostic or therapeutic purposes in nuclear medicine.
  • [18F]FDG: A radioactive form of glucose used in PET imaging to detect cancer and other metabolically active tissues.
  • Thyroid scintigraphy: An imaging test that uses a small amount of radioactive iodine to examine the structure and function of the thyroid gland.
  • Hepatocellular carcinoma (HCC): The most common type of primary liver cancer, usually occurring in people with chronic liver diseases.
  • Metastases: The spread of cancer cells from the primary site to other parts of the body.
  • PSMA: Prostate-Specific Membrane Antigen, a protein found on the surface of prostate cancer cells and some other cancer types.
  • Standard Uptake Value (SUV): A measure of the intensity of tracer uptake in PET imaging, used to quantify the accumulation of radioactive substances in tissues.
  • Tumor-to-background ratio: A measure used in imaging to compare the uptake of a tracer in tumor tissue versus normal surrounding tissue.

References

  1. http://clinicaltrials.eu/trial/study-on-18fpsma-11-pet-imaging-for-patients-with-advanced-thyroid-and-head-and-neck-cancer/
  2. http://clinicaltrials.eu/trial/study-on-f-18-psma-11-pet-imaging-for-liver-cancer-in-patients-to-evaluate-survival/